NorthWest Biotherapeutics Inc (NWBO)

[john1045]

ATLnsider, totally agree with you on your post!

Message in reply to:

Thanks Lykiri, very good information.

But, I do disagree with the authors when they say "these results will need to be replicated before full approval for standard of care."

After the DCVax-L Phase III clinical trial data is unblinded and unblended, the evidence to support DCVax-L worldwide regulatory approvals, and incorporating DCVax-L into the new standard of care (SOC) to treat both ndGBM and rGBM will be overwhelming.

In addition, when you combine the DCVax-L Phase III trial results with the Compassionate Use results, and the Informational Arm results, the results are already replicated and will be more than sufficient to support DCVax-L inclusion into SOC to treat all GBM patients.